SCHEMBL6287762

SCHEMBL6287762

O=C(CN1C(=O)N(C(=O)c2ccc3ccccc3c2)C(=O)C1(c1ccccc1)c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.41
CDYL2 Q8N8U2 4/20 0.39
CDYL Q9Y232 4/20 0.39
CDY1; CDY1B Q9Y6F8 4/20 0.39
CBX7 O95931 3/20 0.39
PTPN1 P18031 1/20 0.38
LMNA P02545 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
HPGD P15428 2/20 0.38
ACHE P22303 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 2/20 0.38
DRD4 P21917 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282035 0.91 BCHE (0.42) BCHECDYL2CDYLCDY1; CDY1BCBX7
SCHEMBL6285250 0.87 CBX7 (0.40) BCHECDYL2CDYLCDY1; CDY1BCBX7
SCHEMBL6282939 0.85 BCHE (0.40) BCHECDYL2CDYLCDY1; CDY1BCBX7
SCHEMBL6283118 0.85 NPC1 (0.49) BCHECDYL2CDYLCDY1; CDY1BCBX7
SCHEMBL6283097 0.85 CBX7 (0.42) BCHECDYL2CDYLCDY1; CDY1BCBX7
SCHEMBL6287739 0.84 TSHR (0.39) BCHEKDM4EALDH1A1MEN1MAPT
SCHEMBL6287758 0.81 BCHE (0.40) BCHECDYL2CDYLCDY1; CDY1BCBX7
SCHEMBL6284743 0.80 TSHR (0.46) BCHECDYL2CDYLCDY1; CDY1BCBX7
SCHEMBL6285680 0.79 CBX7 (0.41) BCHECDYL2CDYLCDY1; CDY1BCBX7
SCHEMBL6282913 0.77 KMT2A (0.46) BCHECDYL2CDYLCDY1; CDY1BCBX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919365-B2 Imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-07-19 US disclosed
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1384715-A1 NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS Senju Pharmaceutical Co., Ltd. (JP) 2004-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs CMA1, TPSD1, TPSB2 BCHE 515/4885CDYL2 3565/4885CDYL 3427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.